Changshan Pharmaceutical announced that its holding subsidiary Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. recently received the “Notice of Acceptance” issued by the State Drug Administration, and that the marketing license application for abenatide injection submitted by Changshan Kaijiegian was accepted by the State Drug Administration.
常山药业：艾本那肽注射液上市许可申请获受理
Changshan Pharmaceutical: Application for marketing license for ebennatide injection accepted
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.